{"name":"Palatin Technologies","slug":"palatin","ticker":"PTN","exchange":"NYSE American","domain":"palatin.com","description":"Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.","hq":"Cranbury, NJ","founded":0,"employees":"29","ceo":"Carl Spana","sector":"Specialty Pharma","stockPrice":15.35,"stockChange":-1.2,"stockChangePercent":-7.25,"marketCap":"$27M","metrics":{"revenue":8963586,"revenueGrowth":0,"grossMargin":-40.2,"rdSpend":14898494,"netIncome":-17307349,"cash":2564265,"dividendYield":0,"peRatio":-6.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Vyleesi patent cliff ($100M at risk)","drug":"Vyleesi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Palatin Technologies Announces FDA Approval of Vyleesi for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women","summary":"The FDA has approved Vyleesi for the treatment of HSDD in premenopausal women.","drugName":"Vyleesi","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Palatin Technologies Reports Third Quarter 2022 Financial Results","summary":"Palatin Technologies reported its third quarter 2022 financial results, with revenue of $1.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOREVaTzJ5bW5WVTNJb3RyT3RRdks2bW8wOHZialZhTWU5d1NueG4yQ0o1czhLTkZmMF9OcFQwWW5iZVdtOU56X29scDFPamgxSGxiZklFVXFyb0tQMXJCeXY3VHBzeG9YeFV3NzZJWGJrRWcwcDR5eHJITTJqdFhlak5FY3dwMkZUMUxzQW9jNmFNN1M4VkdTTEh5LS1zSTVvWkRrQ0JOekdpZGREVlUtZmZFZVBhSkYtNUZSUE5waW9HenROZ294WU52XzN5SDZZY1JxRDA4RlM1ZFBIejAzNWFiOUtaeG1uTTE0VHFGWkpCbS1abEZz?oc=5","date":"2026-02-18","type":"pipeline","source":"TradingView","summary":"Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TradingView","headline":"Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN)","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxQVnkxcjg4RG9icWhEU3llcUhuLUhkQVJreFhQZWRJdW5nLXl4UHNqVEhNZ0xEUFJWSlhCZnhvMDlncElkTUNQNmZzZ2NMVWRtYmVjb19yV1VPN0Vid3ZEdGlKUU1mdTMwZVByNWZVVzZETG9hQ3NRdjNmWm5BbWFnSFB1SkhDeGVMSk13ZFozUjBvek9GZ1c5LThseEVpc2VvWjFPU00zbjJITl9wVE56S2VtS1pWSTdVNzhReXJWSWRmdzRmUkwtNWtFREJ4ajYyMUFjaDFpNlpDaWZuZThpZ0hoRldCUGVZYWZzYjNpbzRnSVYyNDY1YVlfVHVjLUhJWXppQk1oVTVTa3VRSkE0NFl4ek55UmE2NW1qeXhVNmQ3Tl9iRkE?oc=5","date":"2025-11-12","type":"pipeline","source":"PR Newswire","summary":"Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PR Newswire","headline":"Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwrite","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNc3YwRHBMSUEwYng4eHJ0aTRHcU94NW5VLWtCaHhrcWE2VXFfNE1MaDRHZUlxb2NzeGRNZE9SOFdKLU5obVZzOFlWczhOdl8tVDlPeVI4b3BhRjlMdTc4a2g3MXNkTUx2cE0wYVhuVGF0a3hoMXlfNG90WVZuTnFmY09RZVg4TTZoU0ktbWwzdDU2T0xNV09ldkRYZlpKOXg5ZVhWX3RyeDAzOGplMzBKbEJTRExma24yOF9tbHlDRQ?oc=5","date":"2025-05-07","type":"pipeline","source":"Stock Titan","summary":"Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Stock Titan","headline":"Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxObUNuQjRGckZFa0pQcDdBcHd0dW9XSlFQMm9FUEp1SzhkTF9VMEExMWpFcldjY0pKaEV5ME5wUFVsbTRORDhzS0tXVXEtbktRUUFjSlBNQi1MVWc3dkZqOUhxcjQ0WGJ6a3R2VW4yYlJ5VXB6RDhrTTRSSjZKYXBLVnNrX2FtTFk5TVdrYzhQeHVJMVhXZW5Pcms5czRFRFZsVjBPaTVPNERtemRsdnBPMDFuZU1xWXJFNjVkcjJCbDlFSDFGNnFNSGJPWGdiSUxjaGExOTJQSmVqOFBfNmhKMl9ONEFVRWc?oc=5","date":"2024-01-03","type":"deal","source":"Business Wire","summary":"Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. - Business Wire","headline":"Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOU0doZ2RrOFlmVDd2T0xPWkZkd2IwVTNwT1FPQVNvU1BCTnJOSE9UWS1pemVSRERLRHJ2TEJFMElPSnc2cnFtR0VWcjFURkhBLXYwc0o5U0ZlaGhrREU0Y0J1R19HSENwb2ZWbHB6RGxJeGlHOXJlb0lUSENjbzdDLTJ3N1hGelFvd1BiajFVVG1ySlI1aTlvY3BJV2RRX1RFSzRlLW91aVpBTk1NRU5OUmRqVTN0MzVieHFwWE1veTliNkdCTHFpOUdVamNNOTdibGtwdw?oc=5","date":"2023-12-20","type":"pipeline","source":"PR Newswire","summary":"Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million - PR Newswire","headline":"Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE81SmM1MW5OX3Z3T1N6RS1JT0RkNXN5eUN3emtLSVdIVGI0X3A1ajlvTy1lQzhXVTVVb21HQnp2cUZvbXBfQjJKSFJPWV9KSXlLclhpdGZtb3Q?oc=5","date":"2017-07-20","type":"pipeline","source":"TradingView","summary":"PTN Stock Price and Chart — AMEX:PTN - TradingView","headline":"PTN Stock Price and Chart — AMEX:PTN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQNG5PUjNHMFY3YjVVWENJMldsQUdZN2RWT3JKWWZUYlktajRhaWJ0VmMydGNtbXZPZ1cxTkxNcHMtTzFDbjBBQUhqcXBMZGZoQjc5bFZ1U21yVFRaSld0ZFZaazZ3YkN6Z0dEdDNUUTE0M2pZTlUxU1RoRXBQYjQ3bjFSZFNKSmo1VmF3WXJtSEM3SU1GME4xR0xQcWhTSEZzbkxUclJfSUp1Z3FvSEFNb2pUcDVHdDRkRzBSMQ?oc=5","date":"2016-07-04","type":"regulatory","source":"Fierce Pharma","summary":"Catalent inks deal with Palatin to manufacture pen injector to treat female sexual dysfunction - Fierce Pharma","headline":"Catalent inks deal with Palatin to manufacture pen injector to treat female sexual dysfunction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNamZscHdXbGM5bmJFSlRLbmtjOGYzUmplQU5QMTdST01qcVhsbUVhTUZQeFlsNmFBa2xyR1JFcHp4VzN2VGVoSzBDaHlVTU9lVDBmc0dadXpzVDVXMER0TWtVYjBhYjBWaGEyenJjOU5HOHh4SWw4VEhScFJxcUVvb2tyMkdBdWY5SXhhM05EVlQ0bzlTZUt3RjZIWWtQak5qQ2Y2c0lBVnowMnphMmNEQVJ6dHJpU3p0SVVDc3FKYjhtZ0tNOUxZ?oc=5","date":"2015-08-19","type":"regulatory","source":"proactiveinvestors.com","summary":"Palatin Technologies soars as FDA okays first ‘female viagra’ - proactiveinvestors.com","headline":"Palatin Technologies soars as FDA okays first ‘female viagra’","sentiment":"neutral"}],"patents":[{"drugName":"Vyleesi","drugSlug":"bremelanotide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Amag Pharmaceuticals","Valeant Pharmaceuticals","United Therapeutics"],"therapeuticFocus":["Hypoactive Sexual Desire Disorder (HSDD)","Pulmonary Arterial Hypertension (PAH)"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-06-30","revenueHistory":[{"value":0,"period":"2025-06-30"},{"value":4490090,"period":"2024-06-30"},{"value":4853678,"period":"2023-06-30"},{"value":1468457,"period":"2022-06-30"},{"value":-188597,"period":"2021-06-30"},{"value":117989,"period":"2020-06-30"}],"grossProfit":0,"grossProfitHistory":[{"period":"2025-06-30","value":0},{"period":"2024-06-30","value":4392453},{"period":"2023-06-30","value":4435208},{"period":"2022-06-30","value":1250928}],"rdSpend":14898494,"rdSpendHistory":[{"period":"2025-06-30","value":14898494},{"period":"2024-06-30","value":22400372},{"period":"2023-06-30","value":22630577},{"period":"2022-06-30","value":21327434}],"sgaSpend":7809345,"operatingIncome":-22707839,"operatingIncomeHistory":[{"period":"2025-06-30","value":-22707839},{"period":"2024-06-30","value":-30277965},{"period":"2023-06-30","value":-33486205},{"period":"2022-06-30","value":-36588448}],"netIncome":-17307349,"netIncomeHistory":[{"period":"2025-06-30","value":-17307349},{"period":"2024-06-30","value":-29736113},{"period":"2023-06-30","value":-24036741},{"period":"2022-06-30","value":-36198299}],"eps":-32.15,"epsHistory":[{"period":"2025-06-30","value":-32.15},{"period":"2024-06-30","value":-101.16},{"period":"2023-06-30","value":-110.5},{"period":"2022-06-30","value":-189.5}],"cash":2564265,"cashHistory":[{"period":"2025-06-30","value":2564265},{"period":"2024-06-30","value":9527396},{"period":"2023-06-30","value":7989582},{"period":"2022-06-30","value":29939154}],"totalAssets":3266954,"totalLiabilities":8043999,"totalDebt":163781,"equity":-4777045,"operatingCashflow":-21306637,"operatingCashflowHistory":[{"period":"2025-06-30","value":-21306637},{"period":"2024-06-30","value":-31461441},{"period":"2023-06-30","value":-29271346},{"period":"2022-06-30","value":-29922749}],"capex":-42526,"capexHistory":[{"period":"2024-06-30","value":-42526},{"period":"2023-06-30","value":-433927},{"period":"2022-06-30","value":-261374},{"period":"2021-06-30","value":-5722}],"freeCashflow":-21306637,"dividendsPaid":null,"buybacks":null,"employees":29,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3124817,"ebit":-7263363,"ebitda":-7248975,"period":"2025-12-31","revenue":116036,"epsBasic":-2.86,"netIncome":-7263861,"rdExpense":4319767,"epsDiluted":-2.86,"grossProfit":null,"operatingIncome":-7328548},{"sga":1660731,"ebit":4679536,"ebitda":4693923,"period":"2025-09-30","revenue":8847550,"epsBasic":4.81,"netIncome":4677534,"rdExpense":2525766,"epsDiluted":4.26,"grossProfit":null,"operatingIncome":4661053},{"sga":2632551,"ebit":-2226311,"ebitda":-2173318,"period":"2025-06-30","revenue":0,"epsBasic":null,"netIncome":-2229798,"rdExpense":1970103,"epsDiluted":null,"grossProfit":0,"operatingIncome":-4602654},{"sga":1474019,"ebit":-4809625,"ebitda":-4756321,"period":"2025-03-31","revenue":0,"epsBasic":-9,"netIncome":-4811420,"rdExpense":3755158,"epsDiluted":-9,"grossProfit":0,"operatingIncome":-5229177},{"sga":1681844,"ebit":-2438679,"ebitda":-2366849,"period":"2024-12-31","revenue":0,"epsBasic":-5.92,"netIncome":-2442482,"rdExpense":3429479,"epsDiluted":-5.92,"grossProfit":0,"operatingIncome":-5111323},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-19.71,"netIncome":null,"rdExpense":null,"epsDiluted":-19.71,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.35,"previousClose":16.55,"fiftyTwoWeekHigh":31,"fiftyTwoWeekLow":4.5,"fiftyTwoWeekRange":"4.5 - 31.0","fiftyDayAverage":20.5,"twoHundredDayAverage":15.03,"beta":-0.09,"enterpriseValue":15202593,"forwardPE":-6.3,"priceToBook":2.35,"priceToSales":3.03,"enterpriseToRevenue":1.7,"enterpriseToEbitda":-1.23,"pegRatio":0,"ebitda":-12364254,"ebitdaMargin":-137.9,"freeCashflow":-12458299,"operatingCashflow":-15869545,"totalDebt":348788,"debtToEquity":3,"currentRatio":2.76,"returnOnAssets":-70.3,"returnOnEquity":-378.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":54.33,"targetHighPrice":60,"targetLowPrice":50,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":53.8,"sharesOutstanding":1772199,"floatShares":1262125,"sharesShort":145791,"shortRatio":10.47,"shortPercentOfFloat":8.2,"epsTrailing":-8.26,"epsForward":-2.43,"revenuePerShare":7.38,"bookValue":6.53,"officers":[{"age":63,"name":"Dr. Carl  Spana Ph.D.","title":"Co-Founder, President, CEO & Director"},{"age":68,"name":"Mr. Stephen T. Wills CPA, MST","title":"CFO, COO, Executive VP, Treasurer & Secretary"},{"age":null,"name":"Burns  McClellan","title":"Vice President of Investor Relations"},{"age":null,"name":"Mr. Stephen A. Slusher Esq.","title":"Chief Legal Officer"},{"age":65,"name":"Mr. James E. Hattersley B.A., M.S.","title":"Senior Vice President of Business Development"},{"age":null,"name":"Mr. John  Dodd Ph.D.","title":"Senior Vice President of Preclinical Development"},{"age":null,"name":"Mr. Robert  Jordan","title":"Senior Vice President of Program Operations"}],"industry":"Biotechnology","irWebsite":"","website":"https://palatin.com","phone":"609 495 2200"}}